Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues

Clinical Pharmacokinetics

Volumn 35, Issue 1, 1998, Pages 65-77

  Williams, David N ^a   Raymond, Joanne L ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; GENTAMICIN; VANCOMYCIN;

COOPERATION; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG STABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LIVER FUNCTION; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; REVIEW; TEAMWORK;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG STABILITY; FEMALE; HOME INFUSION THERAPY; HUMANS; INFUSIONS, PARENTERAL; MALE; TEICOPLANIN; VANCOMYCIN;

EID: 0031849484     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199835010-00005     Document Type: Review

References (69)

1. Antoniskis A, Anderson BC, Van Volkinhurg EJ, et al. Feasibility of outpatient self-administration of parenteral antibiotics. West J Med 1978; 128: 203-6
2. Stiver HG, Telford GO, Mossey JM, et al. Intravenous antibiotic therapy at home. Ann Intern Med 1978; 89: 690-3
3. Kind AC, Williams DN, Persons G, et al. Intravenous antibiotic therapy at home. Arch Intern Med 1979; 139: 413-5
4. Poretz DM, Eron LJ, Goldenberg RI, et al. Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248: 336-9
5. Rehm SJ, Weinstein AJ. Home intravenous antibiotic therapy: a team approach. Ann Intern Med 1983; 99: 388-92
6. Tice AD. An office model of outpatient parenteral antibiotic therapy. Rev Infect Dis 1991; 13 Suppl. 2: S184-8
7. Tice AD. The team concept: symposium on outpatient parenteral antibiotic therapy. Hosp Pract 1993; 28 Suppl. 1: 6-10
8. Baumgartner JD, Glauser MP. Single daily dose treatment of severe refractory infections with ceftriaxone. Arch Intern Med 1983; 143: 1868-73
9. Winter RJD, Deacock SJ, George RJD, et al. Self-administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis. Lancet 1984; I: 1338-9
10. Grayson ML, Silvers J, Turnidge J. Home intravenous antibiotic therapy: a safe and effective alternative to inpatient care. Med J Aust 1995; 162: 249-53
11. Kayley J, Berendt AR, Snelling MJM, et al. Antimicrobial practice. Safe intravenous antibiotic therapy at home: experience of a UK based programme. J Antimicrob Chemother 1996; 37: 1023-9
12. Gilbert DN, Dworkin RJ, Raber SR, et al. Outpatient parenteral antimicrobial-drug therapy. N Engl J Med 1997; 337: 829-38
13. Francioli P, Etienne J, Hoigne R, et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for four weeks: efficacy and outpatient treatment feasibility. JAMA 1992; 267: 264-7
14. Stamboulian D, Bonhevi P, Arevalo C, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis 1991; 13 Suppl. 2: S160-3
15. Williams DN, Rehm SJ, Tice AD, et al. Practice guidelines for community-based parenteral anti-infective therapy. Clin Infect Dis 1997; 25: 787-801
16. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal phenomena in Barcelona Spain. N Engl J Med 1995; 333 (24): 474-80
17. Hoffman J, Cetron MS, Farley MN, et al. The prevalence of drug-resistant streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333 (24): 481-6
18. Recommendations of the Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. MMWR Morb Mortal Wkly Rep 1994; 44: 1-13
19. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46: 626-8
20. Poretz DM. The infusion center: a model for outpatient parenteral antibiotic therapy. Rev Infect Dis 1991; 13 Suppl. 2: S142-46
21. Tice AD. The office and clinic model for OPAT. Report: a special report from Scientific American Medicine. Proceedings of an OPAT Advisory Board Meeting, 1996 May 16-18; Chicago
22. Williams DN. Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents. Int J Antimicrob Agents 1995; 5: 3-8
23. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 636-42
24. Deguchi Y, Terasaki T, Yamada H, et al. An application of microdialysis to drug tissue distribution study: in vivo evidence for free-ligand hypothesis and tissue binding of beta-lactam antibiotics in interstitial fluids. J Pharmacobiodyn 1992; 15: 78-89
25. Shyu WC, Quintiliani R, Nightengale CH, et al. Effect of protein binding on drug penetration into blister fluid. Antimicrob Agents Chemother 1988; 32: 128-30
26. Scaglione F. Predicting the clinical efficacy of antibioties: toward definitive criteria. Pediatr Infect Dis J 1997; 16: 556-9
27. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet Concepts 1995; 28 (2): 143-60
28. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37 (5): 1073-81
29. Dalla Costa T, Derendorf H. AUIC: a general target for the optimization of dosing regimens of antibiotics. Ann Pharmacother 1996; 30: 1024-31
30. Dudley MN, Mandler HD, Gilbert D, et al. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Am J Med 1987; 82 Suppl. 4A: 363-8
31. Follath F, Bindschedler M, Wenk M, et al. Clinical efficacy of ciprofloxacin in pseudomonas infections. In: Neu HC, Wevta H, editors. Proceedings of the First International Ciprofloxacin Workshop. Amsterdam: Elsevier Science Publishing, 1989: 411-3
32. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to eletermine importance of ratio of antibiotic peak concentration to MIC for bactericical activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-60
33. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155 (1): 93-9
34. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67: 608-11
35. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992; 36 (12): 2577-83
36. Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38 (1): 5-15
37. Klepser ME, Kang SL, McGrath BJ, et al. Influence of vancomycin serum concentration on the outcome of gram-positive infections. American College of Clinical Pharmacy Annual Winter Meeting: 1994 Feb 6-9, San Diego
38. Livernese LL, Benz RL, Ingerman MJ, et al. Antibacterial agents in renal failure. Infect Dis Clin North Am 1995; 9 (3): 591-614
39. Bennett WM, Aronoff JR, Golper TA, et al., edilors. Drug prescribing in renal failure: dosing guidelines for adults. 3rd ed. Philadelphia: American College of Physicians, 1994
40. Haug MT III, Slug PH. Antibiotic pharmacokinetics. In: Sivak ED, Higgins TL, Seiver A, editors. The high risk patient: management of the critically ill. Baltimore: Williams & Wilkins, 1995: 1338-64
41. Tschida SJ, Vance-Bryan K, Zaske DE. Anti-infective agents and hepatic disease. Med Clin North Am 1995; 79 (4): 895-917
42. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
43. Wu G, Furlanut M. Predictions of serum vancomycin concentrations by means of six different equations for calculation of creatinine clearance. Int J Clin Pharmacol Res 1997; 17 (1): 1-10
44. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualized drug therapy: linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualized target goals. Clin Pharmacokinet 1998; 34 (1): 57-77
45. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5
46. Nicolau DP, Nightingale CH, Baneviens MA, et al. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996 Jan; 40 (1): 61-4
47. Weinstein MP, Stratton CW, Hawley HB, et al. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987; 83 (2): 218-22
48. Vinks AA, Brimicombe RW, Heijerman H, et al. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome microbiology and pharmacokinetics. J Antimicrob Chemother 1997; 40 (1): 125-33
49. Nadworny HA, Markowitz A. Parenteral antibiotic therapy at home: experience with intramuscular cefonicid. Clin Ther 1987; 10: 82-91
50. Dagan R, Philip M, Watemberg NM, et al. Outpatient treatment of serious outpatient community-acquired pediatric infections using once-daily intramuscular ceftriaxone. Pediatr Infect Dis J 1984; 3: 514-7
51. Russo TA, Cook S, Gorbach SL. Intramuscular ceftriaxone in home parenteral therapy. Antimicrob Agents Chemother 1988; 32 (4): 1439-40
52. Wagner DK, Collier BD, Rytel MW. Long-term intravenous antibiotic therapy in chronic osteomyclitis. Arch Intern Med 1985; 145: 1073-8
53. Siber GR, Echeverria P, Smith AL, et al. Pharmacokinetics of gentamicin in children and adults. J Infect Dis 1975; 132 (6): 637-51
54. Edelstein HE, Oster SE, Chirurgi VA, et al. Intravenous or intramuscular teicoplanin once daily for skin and soft-tissue infections. DICP Arm Pharmacother 1991; 25: 914-8
55. Verbist L, Tjandramaga B, Hendrickx B, et al. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 1984; 26: 881-6
56. McNulty Jr TJ. Initiation of antimicrobial therapy in the home. Am J Hosp Pharm 1993; 50: 773-4
57. O'Sullivan TL, Ruffing MJ, Lamp KC, et al. Prospective evaluation of Red Man Syndrome in patients receiving vancomycin. J Infect Dis 1993; 168: 773-6
58. Trissel LA. Handbook of injectable drugs. 9th ed. Bethesda: American Society of Health-System Pharmacists, 1996
59. King JC. King guide to parenteral admixtures. St Louis: King Guide Publications, 1996
60. Tice AD. Handbook of outpatient parenteral therapy for infectious diseases. New York: Scientific American, 1997
61. Stiles ML, Allen Jr LV, Prince SJ. Stability of various antibiotics kept in an insulated pouch during administration via portable infusion pump. Am J Health Syst Pharm 1995; 52: 70-4
62. Neftel KA, Walti M, Spengler H, et al. Effect of storage of penicillin-G solutions on sensitization to penicillin-G after intravenous administration. Lancet 1982; 1 (8279): 986-8
63. Neftel KA, Walti M, Schulthess HK, et al. Adverse reactions following intravenous penicillin-G relate to degradation of the drug in vitro. Klin Wochenschr 1984; 62 (1): 25-9
64. Moellering Jr RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? [editorial]. Clin Infect Dis 1994; 18: 544-6
65. Moellering Jr RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94: 343-6
66. James JK, Palmer SM, Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996; 40 (3): 696-700
67. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-22
68. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786-95
69. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809